Gabapentin Tablet, Film Coated
Product Images NDC 71335-1007

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula includes patient age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 applied for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H). This structural formula represents the active ingredient gabapentin.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows the mean pain score from 0 to 10. Gabapentin shows a decreasing trend in pain scores compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain score levels from 0 to 10. Gabapentin groups show a decline in pain scores compared to placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. Study 1 compares PBO (placebo) at 12% response to GBP 3600 at 29%. Study 2 compares PBO at 14% response to GBP 1800 at 32% and GBP 2400 at 34%. Statistical significance markers (p < 0.01 and p < 0.001) are noted for GBP groups versus placebo.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the relationship between daily dose in milligrams and difference percentage for three studies labeled as study a, study b, and study c. The x-axis represents daily dose (600 to 1800 mg), and the y-axis represents difference percentage (7% to 22%). Each study is represented by different colored squares with labels a, b, and c indicating points on the chart.*

FDA Label Image

Label Image (Lbl713351007)

Gabapentin 800 mg tablet label packaged by Bryant Ranch Prepack in Burbank, CA. The label states it is comparable to Neurontin 800 mg tablet by Strides Pharma Science Limited. It includes storage instructions, a lot number, barcode, quantity (#30), and the NDC 71335-1007. The tablet is described as white oval.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.